Exploring the Potential of Artificial Intelligence – June 2023
LSTLF MEETING: JUNE 2023
On June 13, 2023, Osprey Life Sciences was excited to moderate the most recent Life Sciences Technology Leadership Forum (LSTLF) event. The gathering brought together IT leaders from several prominent life sciences organizations in the Boston area. With a specific focus on artificial intelligence (AI) and its potential impact on the life sciences industry, the forum sparked an engaging and insightful discussion that shed light on the benefits and challenges of this rapidly evolving technology.
The lively discourse among industry experts and thought leaders highlighted several key takeaways:
Diverse Adoption: Organizations demonstrated varying degrees of interest and adoption of AI technology. Some were just scratching the surface, others were actively exploring its applications, while still others were further down the path of implementation. The spectrum of engagement highlighted the importance of understanding individual organizational needs and readiness when integrating AI.
The Role of Education: The consensus was clear – education will play a critical role in maximizing the potential of AI in the life sciences sector, along with its appropriate usage. Participants emphasized the need for continuous learning and knowledge-sharing initiatives to ensure that professionals stay informed about the latest advancements and best practices in AI.
Collaborative Partnerships: Success in leveraging AI will likely require partnerships with external experts and technology providers. Participants recognized that acquiring the necessary expertise and accessing cutting-edge AI solutions will be challenging without collaboration, making strategic alliances a valuable avenue for progress.
Risk Management: AI adoption comes with inherent risks. The participants stressed the importance of understanding these risks and proceeding with caution. While embracing AI’s potential, it is crucial to develop a clear understanding of its limitations and vulnerabilities. Thoughtful risk assessment and mitigation strategies will be vital in harnessing the technology effectively.
Balanced Approach: Finding the right balance between caution and enthusiasm is key. Participants acknowledged that being overly cautious or attempting to impede AI adoption might lead to frustration and failure. Instead, a measured and informed approach, supported by continuous evaluation and adaptation, can help organizations navigate the challenges associated with AI implementation.
Legal and Compliance Considerations: Participants recognized the significance of involving legal and compliance teams in developing overarching guidelines and controls for AI usage. Collaboration between technology experts, compliance professionals, and legal advisors will be instrumental in ensuring ethical and responsible AI implementation.
Strategic Advantage: The prevailing sentiment is that embracing AI could provide organizations with a strategic advantage in the highly competitive life sciences landscape. By harnessing the power of AI, companies can enhance research and development, streamline processes, and deliver innovative solutions with greater speed and accuracy.
Intellectual Property (IP) Risks and Considerations: The concerns around patent and intellectual property risks in using AI technologies, like ChatGPT, in biotech organizations can stem from several issues:
- Inadvertent disclosure: Using AI technologies could lead to accidental sharing of confidential or proprietary information. This could happen if sensitive data is used as input to these systems or if results from these systems, containing derived sensitive knowledge, are shared improperly.
- Ownership of IP: When AI is used in the process of invention or creation, there may be confusion or dispute over who owns the resulting intellectual property. This is a new and evolving area of law, with many open questions about how traditional IP rights apply when AI is involved in the creative process.
- Data Privacy: AI systems often need large amounts of data for training and operation. There could be concerns around the privacy and protection of data, particularly in biotech where data could be very sensitive (e.g., patient data).
- AI generated Intellectual Property (IP): AI may generate novel outputs that could be deemed as IP, creating ambiguity about ownership and rights. For example, who owns the IP of a novel molecule discovered by an AI system? The user, the developer of the AI, or the AI itself?
- Copyright and infringement: AI systems can process vast amounts of information, potentially including patented material. If an AI inadvertently uses patented methods or creates similar outputs, that could potentially lead to infringement issues.
The Business will be Creative: Be prepared for the flood of AI requests. After your company deploys the initial set of AI applications, you should prepare for an array of additional potential use-cases from all sectors. These suggestions will focus on the ways AI could address challenges and boost efficiency.
The bottom line of the meeting was that while there is great excitement around the topic with great potential reward, there is also great risk. Organizations are mostly just starting their journey, educating their peers, setting up guide-rails, establishing processes, and understanding the value potential. While there is a lot of buzz out there now, there is still a lot to do regarding leveraging this technology in an effective and safe manner.
With the success of this LSTLF session, we eagerly anticipate the next forum, scheduled to take place this coming September. The discussion topic is yet to be determined; however we are sure it will be no less engaging. Osprey looks forward to fostering an environment that encourages collaboration, innovation, and the exchange of ideas to drive the future of technology in life sciences.